Nanobac Announces Results of Pre-IND Meeting with FDA
Tuesday February 6, 11:15 am ET
TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP - News) "Nanobac" or "the Company" announces the results of a Pre-IND meeting with the FDA on January 19, 2007 to discuss specific details of the plan for developing a treatment for patients with chronic prostatitis, referred to as CP/CPPS, and to discuss the content of the initial IND required to support clinical evaluation.
Nanobac Pharmaceuticals, Inc. and FDA representatives were in agreement on the general approach to the development program and steps leading to an IND submission and the start of clinical trials. "We view this meeting as a positive step in building a collaborative relationship with the FDA and believe the path set out by the FDA will result in meaningful data on the use of our combination therapies against prostatitis," stated Dr. Benedict Maniscalco, Co-Chair and Chief Medical Officer for Nanobac Pharmaceuticals.
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) also referred to as category III prostatitis, is defined by pelvic pain associated with ejaculatory and/or urinating pain/discomfort lasting longer than 3 months. In the United States, more than 2 million men per year will visit their physician for prostatitis.
About Nanobac Pharmaceuticals: Nanobac Pharmaceuticals, Inc. is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs), formerly known as nanobacteria. The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease.
Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: nanobac.com .
Contact:
Nanobac Pharmaceuticals, Inc., Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348 |
